In Stage 3 NSCLC, Cisplatin Plus Etoposide vs. Carboplatin Plus Paclitaxel Show Similar Survival
the Cancer Therapy Advisor take:
According to a new study published in the Journal of Clinical Oncology, etoposide plus cisplatin results in a similar overall survival as carboplatin plus paclitaxel for the treatment of stage 3 non-small cell lung cancer (NSCLC) in a Veterans Health Administration population, but etoposide plus cisplatin was associated with increased morbidity.
For the study, researchers identified 1,842 patients with stage 3 NSCLC who were treated with either etoposide-cisplatin or carboplatin-paclitaxel with concurrent radiation between 2001 and 2010.
Various analyses demonstrated that treatment with etoposide-cisplatin did not result in a longer duration of overall survival compared with treatment with carboplatin-paclitaxel. A Cox proportional hazards model found a hazard ratio of 0.97 (95% CI: 0.85 - 1.10), a propensity score matched cohort determined a hazard ratio of 1.07 (95% CI: 0.91 - 1.24), and a propensity score adjusted model found a hazard ratio of 0.97 (95% CI: 0.85 - 1.10).
In addition, patients treated with etoposide-cisplatin had more hospitalizations (P < 0.001), outpatient visits (P < 0.001), infections (P = 0.0022, kidney injury (P < 0.001), and mucositis/espophagitis (P = 0.0246).
Etoposide plus cisplatin results in a similar overall survival as carboplatin plus paclitaxel for NSCLC.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer
- Expert Panel Provides Recommendations for Running Trials on Intratumoral Immunotherapy
- Large Acute Myeloid Leukemia Dataset Could Help Identify Targeted Treatments
- Treatment of H. pylori Increased Platelet Count in ITP
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD
- Prisoner or Patient? Challenges of Cancer Care in the Incarcerated Population